HUMAN CYTOCHROME 11B2 INHIBITORS Russian patent published in 2022 - IPC C07D471/04 A61K31/437 A61K31/4375 A61K31/4427 A61K31/4523 A61K31/4535 A61K31/5377 A61P9/00 A61P13/12 A61P1/16 A61P9/04 

FIELD: pharmaceutical industry.

SUBSTANCE: invention relates to a compound of the general formula (I) or its pharmaceutically acceptable salt, where R1 is selected independently and is: (C1-C5)-alkyl, which is replaced by a nitrile group, (C3-C7)-cycloalkyl, a 5-6-membered heterocycle containing 1 oxygen atom and/or 1 nitrogen atom and optionally substituted with 1-2 R2 substituents, a 5-6-membered heteroaryl containing 1 sulfur atom and/or 1-2 nitrogen atoms and optionally substituted with 1-2 R3 substituents, a C6-aryl, optionally substituted with 1-4 R4 substituents, a bicycle consisting of a phenyl ring connected to a 5-membered heterocycle, containing -C(=O)-, 1 nitrogen atom and optionally substituted with 1-3 R5 substituents; R2 is selected independently and is hydrogen, -C(=O)-CH₃; R3 is selected independently and is hydrogen, (C1-C3)-alkyl or partially or completely halogenated (C1-C3)-alkyl; R4 is selected independently and represents hydrogen, halogen, (C1-C3)-alkyl, -O(C1-C3)-alkyl, -CONR6''R7''; R5 is selected independently and represents hydrogen, (C1-C3)-alkyl; R6'' is selected independently and represents (C2-C3)-alkyl; R7'' is selected independently and represents (C2-C3)-alkyl; alternatively, R6'' and R7'' together with the nitrogen atom to which they are attached can form a 5-7-membered heterocycle containing 1-3 heteroatoms selected from nitrogen, oxygen and/or sulfur; Q1 is selected independently and is a carbon or nitrogen atom, optionally substituted with hydrogen, halogen; Q2 is selected independently and it is a carbon atom, optionally substituted with hydrogen; Q3 is selected independently and is a carbon atom, optionally substituted with hydrogen, (C1-C3)-alkyl, and (C1-C3)-alkyl may optionally be partially or completely halogenated; Q4 is selected independently and is a carbon or nitrogen atom, optionally substituted with hydrogen; Q5 is selected independently and is a carbon or nitrogen atom, optionally substituted with hydrogen; n is selected independently and represents 1 or 2; dotted bonds mean that the ring is aromatic; or connection 1-(4-((4-( pyridine-2-yl)-2,3-dihydro-1H-pyrrolo[2,3-c]pyridine-1-yl)sulfonyl)phenyl)ethane-1-on with the formula

The invention also relates to a pharmaceutical composition based on the compound of formula (I).

EFFECT: new compounds and a pharmaceutical composition based on them have been obtained that can be used in medicine for the treatment and/or prevention of a disease or condition that is mediated or supported by aldosterone hyper-synthesis.

45 cl, 2 tbl, 18 ex